Presentation Title

Effects of Sertraline Treatment for Young Children with Fragile X Syndrome: Family Perspectives

Location

Guzman 104

Start Date

4-19-2018 2:40 PM

End Date

4-19-2018 2:55 PM

Department

Occupational Therapy

Student Type

Undergraduate

Faculty Mentor

Laura Hess, OTR/L Ph.D.

Presentation Format

Oral Presentation

Abstract/Description

Fragile X syndrome (FXS) is the most common inherited form of intellectual and developmental disability (IDD) and the most common single gene cause of autism spectrum disorder (ASD) (Hess, et al., 2016; NFXF, 2017). FXS is characterized by anxiety, hyperactivity, impulsivity, and sensory processing challenges (Wheeler et al., 2017). Sertraline, trade name Zoloft, a selective serotonin reuptake inhibitor (SSRI) has been used to treat this population. Hess et al., (2016) found benefits from low dose sertraline on social skills, language, visual perception, and fine motor skills for children ages 2-6 years old with FXS. Despite these findings, current FXS literature lacks outcome measures capturing improvements in daily occupations from family perspectives as part of clinical trials.

Current research studies on children with FXS have focused on standardized testing rather than occupational performance. This research incorporates family perspectives via semi-structured interviews to promote an in-depth understanding about FXS and its impact on child and family occupations. In our research, we project our qualitative findings to reflect improvements in occupational performance for the child and family living with FXS, beyond what standardized measures can capture. We hope this study propels future occupational therapists to continue research in FXS to explore occupations as an outcome measure in addition to standardized assessment scores.

Key words:

-Family

-Occupations

-Sertraline

-Behavior

-Fragile X Syndrome (FXS)

-Standardized assessment scores

-Qualitative vs quantitative

-Occupational therapists

-Occupational performance

-Outcome measures

This document is currently not available here.

Share

Import Event to Google Calendar

COinS
 
Apr 19th, 2:40 PM Apr 19th, 2:55 PM

Effects of Sertraline Treatment for Young Children with Fragile X Syndrome: Family Perspectives

Guzman 104

Fragile X syndrome (FXS) is the most common inherited form of intellectual and developmental disability (IDD) and the most common single gene cause of autism spectrum disorder (ASD) (Hess, et al., 2016; NFXF, 2017). FXS is characterized by anxiety, hyperactivity, impulsivity, and sensory processing challenges (Wheeler et al., 2017). Sertraline, trade name Zoloft, a selective serotonin reuptake inhibitor (SSRI) has been used to treat this population. Hess et al., (2016) found benefits from low dose sertraline on social skills, language, visual perception, and fine motor skills for children ages 2-6 years old with FXS. Despite these findings, current FXS literature lacks outcome measures capturing improvements in daily occupations from family perspectives as part of clinical trials.

Current research studies on children with FXS have focused on standardized testing rather than occupational performance. This research incorporates family perspectives via semi-structured interviews to promote an in-depth understanding about FXS and its impact on child and family occupations. In our research, we project our qualitative findings to reflect improvements in occupational performance for the child and family living with FXS, beyond what standardized measures can capture. We hope this study propels future occupational therapists to continue research in FXS to explore occupations as an outcome measure in addition to standardized assessment scores.

Key words:

-Family

-Occupations

-Sertraline

-Behavior

-Fragile X Syndrome (FXS)

-Standardized assessment scores

-Qualitative vs quantitative

-Occupational therapists

-Occupational performance

-Outcome measures